A retrospective analysis of the outcome HIV-positive patients suffering from histoplasmosis and cryptococcosis was under taken. Half of the 10 patients with cryptococcosis in whom various therapies were Instaured proved non-evaluable, In 4 the mycosis was not controlled while in 3, the therapy (fluconazol) proved successful in arresting the progress of the disease. In the 10 patients with histoplasmosis 16 different chemotherapeutic approaches were undertaken; 7 patients were non-evaluable, 6 met no success and 3 proved adequate to confine fungal progress; the latter patients received new triazole, saperconazole, in a patent with both cryptococcosis and histoplasmosis, fluconazol therapy proved inadequate post-therapy was lower for those patients with cryptococcosis.